Enantioseparation and impurity determination of ambrisentan using cyclodextrin-modified micellar electrokinetic chromatography: Visualizing the design space within quality by design framework
Language English Country Netherlands Media print-electronic
Document type Journal Article
PubMed
27425759
DOI
10.1016/j.chroma.2016.06.082
PII: S0021-9673(16)30886-X
Knihovny.cz E-resources
- Keywords
- Ambrisentan, Capillary electrophoresis, Chiral separation, Experimental design, Impurities, Quality by design,
- MeSH
- Borates chemistry MeSH
- Chromatography, Micellar Electrokinetic Capillary * methods MeSH
- Cyclodextrins MeSH
- Sodium Dodecyl Sulfate MeSH
- Phenylpropionates analysis chemistry MeSH
- Calibration MeSH
- Hydrogen-Ion Concentration MeSH
- Drug Contamination MeSH
- Buffers MeSH
- Pyridazines analysis chemistry MeSH
- Reproducibility of Results MeSH
- Quality Control MeSH
- Stereoisomerism MeSH
- Tablets analysis MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- ambrisentan MeSH Browser
- Borates MeSH
- Cyclodextrins MeSH
- Sodium Dodecyl Sulfate MeSH
- Phenylpropionates MeSH
- Buffers MeSH
- Pyridazines MeSH
- Tablets MeSH
A capillary electrophoresis method for the simultaneous determination of the enantiomeric purity and of impurities of the chiral drug ambrisentan has been developed following the Quality by Design principles. The selected separation system consisted of a micellar pseudostationary phase made by sodium dodecyl sulphate with the addition of γ-cyclodextrin. The effects of critical process parameters (capillary length, temperature, voltage, borate concentration, pH, sodium dodecyl sulphate concentration, γ-cyclodextrin concentration) on enantioresolution of ambrisentan and analysis time were extensively investigated by multivariate strategies involving a screening phase and Response Surface Methodology. The Design Space was defined with a desired probability level π≥90%, and the working conditions, with the limits of the Design Space, corresponded to the following: capillary length, 64.5cm; temperature, 22°C; voltage, 30kV (26-30kV); background electrolyte, 100mM borate buffer pH 9.20 (8.80-9.60), 100mM sodium dodecyl sulphate, 50mM (43-50mM) γ-cyclodextrin. A Plackett-Burman design was applied for robustness testing, and a method control strategy was established. The method was fully validated according to the International Conference on Harmonisation guidelines and was applied to ambrisentan coated tablets.
References provided by Crossref.org